Format

Send to

Choose Destination
Clin Cancer Res. 2016 Sep 15;22(18):4539-41. doi: 10.1158/1078-0432.CCR-16-1401. Epub 2016 Jul 28.

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Author information

1
Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut. Scott.Gettinger@yale.edu.
2
Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.

Abstract

Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585.

PMID:
27470969
PMCID:
PMC5653962
DOI:
10.1158/1078-0432.CCR-16-1401
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center